News
Sports
Life
Opinion
Business
Advertise
Obituaries
eNewspaper
Legals
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
NewsOK Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Akero Therapeutics Inc
(NQ:
AKRO
)
24.32
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Akero Therapeutics Inc
< Previous
1
2
3
4
Next >
Crude Oil Moves Lower; Neogen Posts Downbeat Results
October 10, 2023
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 175 points on Tuesday. The Dow traded up 0.53% to 33,781.59 while the NASDAQ rose 0.72% to 13,581.64. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Big Pharma Could Transform Into BioTech Pharma
October 10, 2023
As the word itself says, biotechnology is simply technology based on biology. It uses the knowledge of cellular and biomolecular processes to develop technologies that improve our lives and overall...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
October 10, 2023
Via
Benzinga
Why Startek Shares Are Trading Higher By 29%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
October 10, 2023
Gainers SuperCom Ltd. (NASDAQ: SPCB) shares jumped 89% to $0.6805, after falling 13% on Monday.
Via
Benzinga
4 Analysts Have This to Say About Akero Therapeutics
September 19, 2023
Via
Benzinga
S&P 500 Rises 1%; US Wholesale Inventories Fall In August
October 10, 2023
U.S. stocks traded higher midway through trading, with the Dow Jones gaining over 250 points on Tuesday. The Dow traded up 0.81% to 33,876.62 while the NASDAQ rose 1.23% to 13,650.54. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Akero Therapeutics Stock Is Crashing Today
October 10, 2023
Investors are bailing on the biotech stock after disappointing clinical results for experimental NASH drug efruxifermin (EFX).
Via
The Motley Fool
PagerDuty, John Wiley & Sons, Ventyx Biosciences And Other Big Stocks Moving Lower On Tuesday
October 10, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Liver Disease Focused Akero Therapeutics Stock Sinking Today?
October 10, 2023
Akero Therapeutics Inc (NASDAQ: AKRO) reported a 36-week analysis of SYMMETRY, a 96-week Phase 2b study of efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to
Via
Benzinga
Why Is Ocugen (OCGN) Stock Up 5% Today?
October 10, 2023
Ocugen stock is rising higher on Tuesday thanks to OCGN investors celebrating news of a new clinical trial for its Covid-19 vaccine.
Via
InvestorPlace
Exposures
COVID-19
Analyst Ratings for Akero Therapeutics
June 07, 2023
Via
Benzinga
Analyst Expectations for Akero Therapeutics's Future
June 07, 2023
Via
Benzinga
NET Stock Alert: Cloudflare Discovers New Cyber Vulnerability
October 10, 2023
Cloudflare stock is getting a boost on Tuesday as investors in NET react to the cybersecurity company discovering a new vulnerability.
Via
InvestorPlace
US Stocks Gain; PepsiCo Posts Upbeat Earnings
October 10, 2023
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 50 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.19% to 33,668.96 while the NASDAQ rose 0.16%...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Akero Therapeutics (AKRO) Stock Down 58% Today?
October 10, 2023
Akero Therapeutics (stock is falling hard on Tuesday after the company failed to impress AKRO investors with its clinical trial results.
Via
InvestorPlace
Why Akero Therapeutics Lost More Than Half Its Value, And Dragged Down 89bio
October 10, 2023
Both companies are working on treatments for NASH. But Akero's disappointed in a midstage test.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 10, 2023
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
October 10, 2023
It's time to dive into the biggest pre-market stock movers with all the most recent news moving shares on Tuesday morning!
Via
InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
October 09, 2023
Via
Benzinga
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
September 27, 2023
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 19, 2023
September 19, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 28, 2023
August 28, 2023
Via
Benzinga
Over $15.5M Bet On ModivCare? Check Out These 4 Stocks Insiders Are Buying
August 11, 2023
Although U.S. stocks closed slightly higher on Thursday, there were a few notable insider trades.
Via
Benzinga
Over $2M Bet On Akero Therapeutics? Check Out These 3 Stocks Insiders Are Buying
August 02, 2023
Although U.S. stocks closed mixed on Tuesday, there were a few notable insider trades.
Via
Benzinga
$9.6M Bet On Energy Transfer? Check Out These 4 Stocks Insiders Are Buying
May 24, 2023
Although US stocks closed lower on Tuesday, there were a few notable insider trades.
Via
Benzinga
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease
March 22, 2023
The battle pits 89bio and Akero in nonalcoholic steatohepatitis.
Via
Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For January 27, 2023
January 27, 2023
Via
Benzinga
20 Favorite Biotech & Medical Stocks For 2023
December 28, 2022
The way these stocks are setting up, many of them look great and will be at the forefront this coming year.
Via
Talk Markets
Akero Therapeutics Outlines Expected 2023 Milestones For Lead NASH Program
December 22, 2022
Via
Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
December 19, 2022
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.